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Abstract: The potential of poly (lactic-co-glycolic acid) nanoparticles (PLGA NPs) to overcome
the intestinal barrier that limits oral liraglutide delivery was evaluated. Liraglutide-loaded PLGA
NPs were prepared by the double emulsion solvent evaporation method. In vitro release kinetics
and enzymatic degradation studies were conducted, mimicking the gastrointestinal environment.
The permeability of liraglutide solution, liraglutide-loaded PLGA NPs, and liraglutide in the
presence of the absorption enhancer PN159 peptide was tested on the Caco-2 cell model. Liraglutide
release from PLGA NPs showed a biphasic release pattern with a burst effect of less than 15%.
The PLGA nanosystem protected the encapsulated liraglutide from the conditions simulating the
gastric environment. The permeability of liraglutide encapsulated in PLGA NPs was 1.5-fold higher
(24 × 10−6 cm/s) across Caco-2 cells as compared to liraglutide solution. PLGA NPs were as effective
at elevating liraglutide penetration as the tight junction-opening PN159 peptide. No morphological
changes were seen in the intercellular junctions of Caco-2 cells after treatment with liraglutide-PLGA
NPs, confirming the lack of a paracellular component in the transport mechanism. PLGA NPs,
by protecting liraglutide from enzyme degradation and enhancing its permeability across intestinal
epithelium, hold great potential as carriers for oral GLP-1 analog delivery.
Keywords: liraglutide; GLP-1 analog; oral peptide delivery; enzymatic barrier; intestinal permeability;
PLGA nanoparticles; Caco-2 cells
1. Introduction
The worldwide prevalence of type 2 diabetes mellitus (T2DM) has been increasing dramatically
and has become a serious issue at an alarming rate. Because the incretin effect has been proven to be
severely reduced or lost in relatively lean type 2 diabetic patients, incretin-based therapy, especially
glucagon-like peptide 1 (GLP-1) receptor agonists, is now widely investigated for T2DM [1]. Long acting
GLP-1 analogs have been developed to overcome the clinical limitations of the native GLP-1 due to its
short circulating half-life [2,3].
Liraglutide (Lira; MW: 3751.2 Da) is an acylated derivative of GLP-1 that shares 97% homology
to the native GLP-1, with two modifications: an Arg34Lys substitution, and a fatty acid side chain
Pharmaceutics 2019, 11, 599; doi:10.3390/pharmaceutics11110599 www.mdpi.com/journal/pharmaceutics
Pharmaceutics 2019, 11, 599 2 of 13
(16-carbon palmitate) attached to Lys26 via a glutamic acid linker [4,5]. Lira retains the physiological
activities of GLP-1 with a considerably longer half-life (approximately 13 h) that supports once-daily
dosing. Subcutaneous Lira has been EMA and FDA approved for T2DM treatment, and soon after
was approved for chronic weight management [6]. As Lira is limited to administration parenterally,
the development of a patient-friendly delivery should be aimed for. Herein, oral administration is the
most attractive choice as this route likely mimics physiological GLP-1 secretion in addition to ensuring
good patient adherence to the treatment [7,8]. Moreover, oral delivery appears to be feasible for Lira
due to the relatively large safety window of GLP1 analogs compared to insulin [9]. However, the oral
delivery of Lira is still challenging due to low stability along the gastrointestinal (GI) tract and poor
intestinal permeability that result in low oral bioavailability [10].
The encapsulation of peptides into nanocarrier systems, especially polymeric NPs, has arisen as
a very promising alternative carrier system that has greater stability in biological fluids and during
storage when compared to lipid-based nanosystems [11]. Polymeric NPs can not only protect the
encapsulated peptide from the harsh environment in the GI tract but also control drug release and
enhance its intracellular uptake [12,13]. Poly (lactic-co-glycolic acid) (PLGA) nanoparticles showed
potential results as nanocarriers designed for the oral delivery of insulin and exenatide [14–17].
To enhance the delivery of protein or peptide molecules across biological barriers, several strategies
can be used. One of them is the opening of intercellular tight junctions [18]. Another possibility is the
use of cell penetrating peptides (CPPs). CPPs comprise a family of functional carrier peptides consisting
of 5–30 amino acid residues that have been reported to have great potential in enhancing the peptide
drugs permeability across the intestinal epithelium. Amphipathic CPPs, such as penetratin, are among
the most widely promising ones. Many recent studies proved that the non-covalent intermolecular
interaction between penetratin and insulin could be clinically promising as an absorption enhancer for
successful oral insulin delivery [19–22]. Our group has recently demonstrated, that a permeability
enhancing 18-mer amphiphilic peptide, PN159, also known as KLAL or MAP, has a dual action:
by acting on claudin transmembrane tight junction proteins it opens the paracellular route in both
epithelial and blood–brain barrier models [23] and at the same time it has cell permeabilizing and
penetrating properties [24].
As realizing the dream of administering antidiabetic peptides such as liraglutide orally is still an
elusive goal, we reported in our previous paper the potential of implementing the quality by design
methodology from the early stage of product formulation, especially when dealing with complex
nanosystems such as polymeric NPs designed for peptide delivery. We have successfully optimized the
formulation of Lira encapsulated in hydrophobic PLGA NPs. For the present work, the purpose was
to evaluate the effectiveness of our previously developed PLGA NPs in protecting the encapsulated
peptide from the harsh environment in the GI tract. As there is no available literature regarding the
intestinal permeability of Lira solution, we also evaluated the permeability of Lira through the Caco-2
cell model. Moreover, we investigated the potential of the optimized PLGA NPs in enhancing the
permeability of encapsulated Lira through the Caco-2 cell model and compared it with the permeability
enhancer PN159 peptide.
2. Materials and Methods
2.1. Materials
Liraglutide was purchased from Xi’an Health Biochem Technology Co., Ltd. (Shaanxi,
China), Poly(lactide-co-glycolide) (PLGA 50:50, Mw = 30,000–60,000 Da), and PVA (MOWIOL 4-98,
Mw ~ 27,000 Da) were purchased from Sigma Aldrich (Munich, Germany). d-mannitol was purchased
from Molar Chemicals Ltd. (Budapest, Hungary). Sodium acetate anhydrous was purchased from
Scharlau Chemie S.A. (Barcelona, Spain). Ethyl acetate was from REANAL Labor (Budapest, Hungary).
Pepsin from porcine gastric mucosa, powder (≥400 units/mg protein) and pancreatin from porcine
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pancreas (≥3× USP specifications) were purchased from Sigma Aldrich (Budapest, Hungary). All other
chemicals in the study were of analytical reagent grade.
2.2. Human Caco-2 Intestinal Epithelial Cell Line
The Caco-2 intestinal epithelial cell line was purchased from ATCC (cat.no. HTB-37) at passage 60.
The cells were grown, as previously reported [24], in Dulbecco’s modified Eagle’s medium (Gibco,
Life Technologies, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Pan-Biotech GmbH,
Aidenbach, Germany) and 50 µg/mL gentamycin in a humidified incubator with 5% CO2 at 37 ◦C.
All plastic surfaces were coated with 0.05% rat tail collagen in sterile distilled water before cell seeding
in culture dishes and the medium was changed every 2 days.
2.3. Preparation of PLGA NPs
The Lira loaded PLGA NPs were prepared by the double emulsion solvent evaporation method and
then lyophilized as described previously [25]. Following the initial risk assessment-based study [26],
the Plackett–Burman screening design of the experiment was applied by our research group to optimize
the lyophilized Lira loaded PLGA NP formulation regarding four critical quality attributes namely:
particle size, polydispersity index, encapsulation efficiency and zeta potential [25]. The optimized
formula is shown in Table 1.
Table 1. Optimized Lira loaded PLGA NPs; where PVA is the polyvinyl alcohol-stabilizer, and W2/O is
the outer aqueous phase to organic phase ratio.
Formulation Parameters
PLGA amount 60 mg
Lira amount 5 mg
2nd sonication time 0.5 min
PVA amount 1.48%
Lyoprotectant type Mannitol
Lyoprotectant amount 5%
W2/O ratio 5
2.4. Preparation of Lira and PN159 Solutions
PN159 peptide (NH2-KLALKLALKALKAALKLA-amide) was previously synthesized and
purified as reported by our research group [23,24]. To prepare Lira and PN159 solutions, liraglutide
was dissolved in cell culture medium or Ringer-buffer (136 mM NaCl, 0.9 mM CaCl2, 0.5 mM MgCl2,
2.7 mM KCl, 1.5 mM KH2PO4, 10 mM NaH2PO4, pH 7.4) in a plastic vial. PN159 was weighed in a
plastic vial and dissolved in Ringer buffer as well. Equal volumes of Lira and PN159 solutions were
gently mixed at room temperature. The final concentrations of liraglutide and PN159 were 100 µM
and 3 µM, respectively, in all experiments.
2.5. In Vitro Drug Release Study
The in vitro release behavior of Lira from the prepared PLGA nanoparticles was assessed by
dispersing Lira-loaded PLGA NPs (corresponding to 500 µg of Lira) in 10 mL of simulated gastric fluid
without enzymes (SGFsp: 0.1 N HCl at pH 1.2). After 2 h, the NPs were centrifuged and transferred to
simulated intestinal fluid without enzymes (SIFsp: phosphate buffer saline at pH 7.4).
The beaker was placed over a magnetic stirrer (100 rpm) and the temperature was kept at 37 ± 1 ◦C
throughout the experiment. At specified time points (0, 0.5, 1, 2, 3, 4, 6 h), an aliquot of 500 µL
was withdrawn from the release medium and replenished with the same volume of fresh preheated
medium. Samples were centrifuged at 16,500× g and 4 ◦C for 10 min, and the Lira concentrations in
the supernatant were determined by HPLC. The cumulative percentage of Lira released was calculated
and then plotted versus time. All experiments were conducted in triplicate.
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2.6. Release Kinetics Studies
To understand the in vitro release from PLGA NPs, the data were fitted into various kinetic models,
which were the zero order (where the drug release rate is independent of its concentration), and first
order model (where the drug release rate is concentration-dependent), and Higuchi (which describes
the drug release from an insoluble matrix as a square root of the time-dependent process based on
Fickian diffusion). The best-fit model was selected based on the coefficient of correlation R2. Then the
release mechanism was further confirmed by fitting the release data in the Korsmeyer–Peppas equation,
where the exponent (η) value was used to describe the release mechanism of the drug through the PLGA
matrix; where 0.45 ≤ η corresponds to the Fickian diffusion mechanism, 0.45 < η < 0.89 corresponds to
anomalous (non-Fickian) transport, η = 0.89 corresponds to case II (relaxational) transport, and η > 0.89
corresponds to super case II transport.
2.7. Enzymatic Degradation Study
Stability analysis in the presence of pepsin and pancreatin was conducted and compared between
native Lira and Lira loaded in PLGA NPs. Five hundred micrograms of native Lira, or the amount of
NPs containing an equivalent amount of Lira, were added to 2 mL of pepsin-containing simulated
gastric fluid SGF (3.2 g pepsin, 2 g of sodium chloride, 7 mL HCl, mixed and diluted with water to 1 L,
pH = 1.2) or pancreatin-containing simulated intestinal fluid SIF (10 g pancreatin, 6.8 g KH2PO4, mixed
and adjusted with 0.2 N NaOH then diluted with water to 1 L, pH = 6.8) and incubated at 37 ◦C under
stirring at a speed of 100 rpm. The SGF and SIF were prepared as per USP specifications (Test Solutions,
United States Pharmacopeia 35, NF 30, 2012). The same methodology was followed to assess the native
Lira stability in SGFsp and SIFsp. The samples (750 µL) were withdrawn at specified time intervals for
2 h, and an equal volume of ice-cold reagent was added: 0.1 M NaOH for SGF and 0.1 M HCl for SIF,
to stop the enzymatic reaction. The samples were centrifuged at 16,500× g and 4 ◦C for 10 min and
the supernatant was analyzed by HPLC to calculate the residual Lira. All incubations were done in
triplicates. Lira recovery in the withdrawn samples was calculated using the following equation:
Lira recovery% = (Remaining Lira amount/theoretical Lira amount) × 100
2.8. Treatment of Caco-2 Cells
The concentration of stock solutions for cell culture experiments were 1 mM for both the therapeutic
peptide liraglutide and the PN159 peptide, which was used as a reference absorption enhancer [23,24].
The working solutions were diluted in cell culture medium or Ringer-buffer depending on the
experiments. The final concentration of liraglutide encapsulated in the PLGA NPs was 100 µM and
was diluted directly before using. Liraglutide was examined at 100 µM, while PN159 was examined at
3 µM concentration both for cell viability and permeability.
2.9. Cell Viability Measurement by Impedance
Impedance was measured at 10 kHz by an RTCA SP instrument (RTCA-SP instrument,
ACEA Biosciences, San Diego, CA, USA). We have successfully tested the cellular effects of peptides
and pharmaceutical excipients by impedance kinetics [23,27,28]. For background measurements,
50 µL cell culture medium was added to the wells. This was followed by seeding the cells at a density
of 6 × 103 cells/well to 96-well plate with gold electrodes (E-plate 96, ACEA Biosciences) coated with
collagen. Cells were cultured for 5 days in a CO2 incubator at 37 ◦C and monitored every 10 min
until the end of experiments. Cells were treated at the beginning of the plateau phase of growth.
Lira, Lira-loaded PLGA NPs, blank PLGA NPs (without cargo), Lira and PN159 solution, and PN159
peptide were diluted in cell culture medium and the effects were followed for 24 h. Triton X-100
detergent (1 mg/mL) was used as a reference compound to obtain total cell toxicity. Cell index was
Pharmaceutics 2019, 11, 599 5 of 13
defined as Rn-Rb at each time point of measurement, where Rn is the cell–electrode impedance of the
well when it contains cells and Rb is the background impedance of the well with the medium alone.
2.10. Permeability Study on the Caco-2 Model
Transepithelial electrical resistance (TEER) reflects the overall tightness of cell layers of biological
barriers. TEER monitoring was performed by an EVOM volt-ohmmeter (World Precision Instruments,
Sarasota, FL, USA) combined with STX-2 electrodes. The final TEER was expressed relative to the
surface area of the monolayers as Ω × cm2 after subtraction of TEER values of cell free inserts.
Caco-2 cells were seeded onto Transwell inserts (polycarbonate membrane, 3 µm pore size,
1.12 cm2 surface area; Corning Life Sciences, Tewksbury, MA, USA) and cultured for three weeks [29,30].
For transport experiments, the inserts were transferred to 12-well plates containing 1.5 mL Ringer-buffer
in the acceptor (lower/basal) compartments. In the donor (upper/apical) compartments, the culture
medium was replaced by 0.5 mL Ringer-buffer containing treatment solutions of Lira, Lira loaded
in PLGA NPs, and Lira and PN159 solution at the concentration of 100 µM for liraglutide for 1 h.
Treatment solutions from both compartments were collected and the Lira level was detected by HPLC.
The apparent permeability coefficients (Papp) were calculated as described previously [23].
Briefly, the cleared volume was calculated from the concentration difference of the tracer in the
acceptor compartment (∆[C]A) after 1 h and the donor compartments at 0 h ([C]D), the volume of the
acceptor compartment (VA; 1.5 mL) and the surface area available for permeability (A; 1.1 cm2) using
this equation:
Papp(cm/s) =
∆[C]A ×VA
A× [C]D × ∆t
Recovery (mass balance) was calculated according to the equation:
%Recovery =
CDf V
D + CAf V
A
CD0 V
D
× 100%
where CD0 and C
D
f are the initial and final concentrations of the compound in the donor compartment,
respectively; CA0 is the final concentration in the acceptor compartment; and V
D and VA are the volumes
of the solutions in the donor and acceptor compartments [29].
2.11. Immunohistochemistry
Aiming to investigate the morphological changes in interepithelial junctions, immunostaining
for the junctional proteins, zonula occludens protein-1 (ZO-1) and β-catenin, was carried out.
Cells were grown on glass coverslips (Menzel-Glaser, Braunschweig, Germany) at a density of
4 × 104 cells/coverslips for 4 days and treated with Lira (100 µM), Lira loaded in PLGA NPs, Lira and
PN159 solution, and PN159 peptide (3 µM) solutions for 1 h. After the treatment, the coverslips were
washed with phosphate buffer (PBS) and the cells were fixed with 3% paraformaldehyde solution for
15 min at room temperature and incubated in 0.2% TX-100 solution for permeabilization. The cells
were blocked with 3% bovine serum albumin in PBS and incubated with the rabbit primary antibodies,
anti-ZO-1 and anti-β-catenin, overnight. Incubation with secondary Cy3-labeled anti-rabbit antibody
lasted for 1 h. Hoechst dye 33342 was used to stain the cell nuclei. After mounting the samples
(Fluoromount-G; Southern Biotech, Birmingham, AL, USA), the staining was visualized by a Visitron
spinning disk confocal system (Visitron Systems GmbH, Puchheim, Germany).
2.12. Chromatographic Equipment and Conditions
Lira was analyzed by a reversed phase HPLC (Agilent 1200, San Diego, CA, USA) method that
was previously developed and validated in our lab [25]. A Kinetex® C18 column with dimensions of
(5 µm, 150 × 4.6 mm, (Phenomenex, Torrance, CA, USA) was used as the stationary phase. The mobile
phase comprised 0.02 M aqueous KH2PO4 solution (pH = 7.0, solvent A) and acetonitrile (solvent B)
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was pumped in a gradient mode from 80:20 (A:B, v/v) to 30:70 (A:B, v/v) in 12 min then back to
80:20 (v/v) between 12.1–15 min, at a flow rate of 1.5 mL/min. Fifty microliters of the sample was
injected. The wavelength of UV detection was 214 nm. The retention time of Lira was 8.65 min.
The regression of the linearity (R2) of the Lira calibration curve was 0.996.
2.13. Statistical Analysis
All data presented are means ± SD. The values were compared using the analysis of variance
(ANOVA) followed by the Dunnett test or the Bonferroni test, using GraphPad Prism 5.0 software
(GraphPad Software Inc., San Diego, CA, USA). Changes were considered statistically significant
at p < 0.05.
3. Results
3.1. In Vitro Release of Lira from PLGA NPs
The release behavior data presented in (Figure 1) showed a biphasic release pattern starting by a
moderate initial burst release during the first 2 h in SGFsp, where 14.2 ± 0.86% of Lira was released from
the NPs. This was followed by a slow release profile until 6 h in the SIFsp, where only 18.5 ± 2.39% of
cumulative Lira release was reached.
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Korsmeyer-Peppas 1.3162 0.762 0.9993 0.2456 1.0696 0.9996
Figure 1. lative in vitro release profile of liraglutide (Lira) from PLGA NPs.
3.2. Release Kinetics Studies
Based on the best fit with the highest correlation (R2) value, it is concluded that Lira release from
PLGA NPs follows the zero-order model (R2 = 0.999) in SGFsp (pH = 1.2). When the release data is
fitted into the Korsemeyer–Peppas equation (R2 = 0.999), the exponent (n) value is 1.316, which is
consistent with the zero-order release mechanism (Table 2).
Regarding the following 4 h in SIFsp, the release mechanism follows the Higuchi model (R2 = 0.998),
indicating diffusion-controlled release, and the exponent (n) value of the Korsmeyer–Peppas equation
is 0.254, indicating that the release mechanism from PLGA NPs follows the Fickian diffusion mechanism
(Table 2).
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Table 2. Release kinetics data of Lira from PLGA NPs, in SGF and SIF (without enzymes).
Kinetic Model
SGF SIF
N k R2 n k R2
Zero order 7.9857 1.84 0.9991 0.9836 12.658 0.9925
First order 0.038 2.01 0.998 0.0052 1.9418 0.9934
Higuchi 17.049 10.262 0.9854 4.1563 8.3559 0.9983
Korsmeyer-Peppas 1.3162 0.762 0.9993 0.2456 1.0696 0.9996
3.3. Enzymatic Degradation Study
It is obvious that only 1.9 ± 0.46% and 9.2 ± 0.7% of the free Lira was recovered after 30 min
incubation in SGF and SIF, respectively. Lira was completely degraded after incubation for 1 h in SIF,
while only 5.7 ± 0.53% Lira recovery occurred after 2 h incubation with SGF. On the other hand, the
encapsulation of Lira into PLGA NPs was able to successfully protect 71.2 ± 1.49% and 87.6 ± 1.3% of
Lira from degradation in the SGF and SIF at the end of the 2-h incubation, respectively (Figure 2). PLGA
nanoparticles were claimed in previous research papers to be able to provide a protective and stable
environment to encapsulate peptide drugs [11,31]. Encapsulation of GLP-1 into PLGA nanosystems
could successfully shelter the peptide from the harsh environment of the simulated conditions of the
stomach with sustained GLP-1 release [12].
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3.4. Cell Viability Assay
Treatments with Lira, Lira loaded in PLGA NPs, Lira with PN159 peptide, unloaded PLGA NPs
or PN159 peptide did not change the cell index values measured by impedance, a sensitive method
to detect cellular effects, indicating good cell viability (Figure 3). Figure 3A shows the kinetics of the
cellular effects of the treatment solutions, while the columns in Figure 3B show the effect of treatments
at the 1-h time point. When cells were lysed with the detergent Triton X-100 the impedance dropped to
zero (Figure 3B).
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3.5. Permeability Study on the Caco-2 Intestinal Barrier Model
Caco-2 monolayers showed high TEER values (893 ± 135 Ω × cm2, n = 20) before permeability
experiments indicating tight barrier properties. Because of the tight barrier the permeability was low
for the marker molecule fluorescein (Papp: below 0.5 × 10−6 cm/s) as in our previous study [29]. The free
Lira at a donor concentration of 100 µM showed good penetration as the Papp was 16 × 10−6 cm/s
(Figure 4). The permeability of Lira encapsulated in NPs, 24 × 10−6 cm/s, was significantly higher than
that for Lira solution. An increased Lira permeability (28 × 10−6 cm/s) was measured in the presence
of PN159 peptide, our reference absorption enhancer (Figure 4A). There was no statistical difference
between the liraglutide permeability values of the Lira-NP and Lira + PN159 groups. In contrast, the
only group where the TEER values dropped after the 1-h treatment was the one containing PN159
peptide (Figure 4B) indicating opening of the paracellular pathway in agreement with observations
from our previous studies [23,24]. Liraglutide alone or encapsulated in PLGA NPs did not change the
ionic permeability (Figure 4B), suggesting no toxic effect on differentiated Caco-2 cells in concordance
with the viability data (Figure 3) and no effect on the paracellular pathway.
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Figure 4. Evaluation of per eability of liraglutide (100 µ ) across aco-2 epithelial cell layers treated
with different liraglutide formulations for 1 h (A). Changes in transepithelial electrical resistance (TEER)
values of Caco-2 cell layers after 1-h treatment with different liraglutide formulations as compared
to TEER values before treatment (B). Values are presented as means ± SD, n = 4. Statistical analysis:
ANOVA followed by Bonferroni test, *** p < 0.001 compared to liraglutide group.
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There was a good recovery for Lira after the permeability experiments and we found no significant
differences between the recovery values of the different investigated Lira groups (Table 3).
Table 3. Recovery (mass balance) calculation after liraglutide permeability on Caco-2 cells.
Liraglutide Recovery (%) Mean ± SD
Liraglutide 80.9 ± 1.6
Liraglutide in NPs 75.3 ± 2.3
Liraglutide + PN159 81.3 ± 6.9
3.6. Immunohistochemistry
The Caco-2 intestinal epithelial cells formed confluent layers visualized by the localization of
the junctional proteins ZO-1 and β-catenin. The cells were attached to each other without gaps and
had similar immunostaining patterns. An intact, belt-shaped continuous localization around the cell
borders for the junctional proteins was observed both in the control and the treated groups. Only the
PN159 peptide treated group showed a visible change in the staining pattern of β-catenin adherens
junctional protein (Figure 5).Pharmaceutics 2019, 11, x 9 of 13 
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4. Discussion
GLP-1 analogs represent a unique class of antidiabetic peptide drugs with potential clinical
benefits over existing therapies for T2DM treatment [32]. Lira, a lipophilic long-acting GLP-1 analog,
is still subcutaneously administered. Since the oral delivery of Lira can bypass the inconvenience
zone of patients, a smart carrier system that can tackle the challenges hindering the oral peptide
delivery has been aimed for. In a previous work, we formulated and statistically optimized the
formulation and p ocess par meters affecting t e quality of Lira loaded PLGA NPs that are designed
for oral delivery. Spherical shaped NPs with homogeneous distribution 188.95 nm particle size and
51.81% encapsulation efficiency wer obtained [25]. As a follow-up study, the im of this work was
to investigate the potential of the developed PLGA NPs in overcoming the main barriers limiting
the oral peptide delivery, namely, the harsh environment through the GI tract and the absorption
membrane barrier.
The behavior of drug release from polymeric NPs is a complex process attributed to diffusion
followed by degradation and influenced by the drug physicochemical properties in addition to various
formulation and process variables [33]. The Lira release from PL NPs showed a biphasic release
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pattern, which was frequently reported for polymeric NPs by previous papers [12,34]. At the burst
release phase (where less than 15% of Lira was released), PLGA NPs are exposed to the gastric media
and the surface of the NPs is hydrated. Then, non-capsulated Lira, or Lira which exists close to
the surface having weak interactions with it is easily accessible by hydration and is released in the
media. Potentially, less than 15% of Lira was released from NPs in the gastric media following a
zero-order model. At the second phase of slow Lira release, the degradation of the polymer matrix took
place, leading to diffusion of the encapsulated Lira, and the release mechanism followed the Higuchi
model, which further confirms the diffusion-controlled release. These results prove that the PLGA
nanosystem is able to hinder the release of encapsulated peptides in gastric simulating conditions
without enzymes (SGFsp), and later sustain the peptide release in intestinal simulating conditions
without enzymes (SIFsp).
The enzymatic stability results were compared between the free Lira and Lira encapsulated in
NPs. There was no Lira detected after the 2-h incubation of free Lira with SGF or SIF, which is due
to the presence of amino acids, especially the aromatic ones, in the Lira structure, which makes it
vulnerable to pepsin–pancreatin digestion [35]. The results revealed that PLGA NPs were effective
in protecting 71% and 87% of Lira from pepsin and pancreatin digestion after a 2-h incubation with
SGF and SIF, respectively. These findings confirm that PLGA NPs can provide a physical barrier
between the encapsulated Lira and the harsh environment in the GI tract, and thereby are promising
for obtaining higher oral peptide bioavailability [12,36].
There was no decrease in cell impedance kinetics regarding the five treatment groups; Lira, Lira
loaded in PLGA NPs, Lira and PN159 peptide in solution, unloaded PLGA NPs or PN159 peptide,
during the 24-h long treatment. These findings proved the biocompatibility of PLGA NPs and showed
that the composition of the nanosystem did not contribute to toxicity in Caco-2 cells. This is in
accordance with previous reports where PLGA nanosystems larger than 100 nm did not trigger any
toxic effects at different concentrations [37–39]. Regarding PN159 peptide, the absence of cytotoxic
effects at the concentration of 3 µM is also in accordance with our previous report [24,40].
To further evaluate the potential of the prepared nanosystem, permeability studies on the Caco-2
cell model were conducted. Lira showed a good apparent permeability through the cell model
compared to what was reported for the native GLP-1 or exenatide, which could be due to the 16-carbon
fatty acid chain that is attached to lysine at position 26 via a glutamic acid spacer [9]. This acylation
leads to higher Lira hydrophobicity [41], which can enhance the intracellular permeability of this
GLP-1 analog when compared to the native GLP-1 or exenatide [42]. The potential of the optimized
polymeric NPs was also investigated to further enhance Lira permeability. Lira encapsulated in NPs
showed 1.5-fold higher apparent permeability as compared to Lira alone. Because PLGA NPs are more
lipophilic compared to the free peptide drug, their transport across the lipid membrane of Caco-2 cells
is better. Furthermore, these optimized polymeric NPs showed a smaller size than 200 nm, and it was
previously reported that NPs within the 100–200 nm size range showed the best properties for cellular
uptake, while smaller-sized (50 nm) or larger-sized (≥500 nm) particles resulted in reduced uptake [43].
Moreover, the prepared NPs were spherical with a smooth surface, as previously confirmed by scanning
electron microscopy [25], which is better for cellular uptake when compared to needle-shaped ones.
The ability of PLGA NPs to enhance the in vitro permeability of the hydrophilic drug alendronate [44],
salmon calcitonin [45], bovine serum albumin [46], and insulin [15,17] through the Caco-2 cell model
has been reported in the literature. In the presence of PN159 peptide, our reference absorption enhancer,
Lira permeability also increased. This finding is consistent with our results, and results from the
literature, on the reversible tight junction opening by the PN159 peptide in biological barrier models,
which effectively improves the permeability of different drugs and hydrophilic marker molecules
through the paracellular pathway [23,24,40]. In addition, it was reported that this amphipathic CPP
can strongly bind to and interact with biological membranes due to electrostatic and hydrophobic
interactions [47,48], and we also confirmed the cell permeabilizing and penetration effects of PN159 on
Caco-2 cells [23].
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The immunostaining for the junctional proteins, ZO-1 and β-catenin, showed that Lira-PLGA
NPs did not change the morphology of interepithelial junctions. The PN159 peptide treated group
showed a change in the staining pattern of the β-catenin adherens junctional protein, which is also
in accordance with our previous results [23,24]. We suppose that an increase in both the paracellular
transport and the membrane permeability in Caco-2 cells by PN159 can contribute to the enhanced
Lira permeability.
5. Conclusions
Being a relatively new GLP-1 analog, there are no reported studies for Caco-2 permeability of
liraglutide alone or encapsulated into a carrier system. In this study we found that the developed
PLGA nanosystem could efficiently protect the encapsulated liraglutide from the conditions simulating
the harsh environment in the GI tract. This polymeric system seems to be promising as it can also
enhance the permeability 1.5-fold compared to free liraglutide solution. These findings reveal that
encapsulation in a polymeric nanosystem holds promise for oral GLP-1 analog delivery.
Author Contributions: Conceptualization, R.I., M.A.D. and I.C.; methodology, R.I, A.B, G.K. and M.A.D.; software,
R.A., A.B. and G.K.; validation, R.I. and A.B.; formal analysis, R.I., A.B., G.K. and I.G.; investigation, R.I., A.B.,
G.K. and I.G.; resources, R.I. and A.B.; data curation, R.I., A.B., G.K. and I.G.; writing—original draft preparation,
R.I. and A.B.; writing—review and editing, R.I., I.G., M.A.D and I.C.; visualization, R.I. and I.G.; supervision,
M.A.D. and I.C.; project administration, I.Cs.; funding acquisition, I.C.
Funding: This work was supported by the Ministry of Human Capacities, Hungary (grant
20391-3/2018/FEKUSTRAT), the National Research, Development and Innovation Office, Hungary
(GINOP-2.2.1-15-2016-00007) and the EU-funded Hungarian grant EFOP-3.6.1-16-2016-00008.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Hinnen, D. Glucagon-like peptide 1 receptor agonists for type 2 diabetes. Diabetes Spectr. 2017, 30, 202–210.
[CrossRef] [PubMed]
2. Gupta, V. Glucagon-like peptide-1 analogues: An overview. Indian J. Endocrinol. Metab. 2013, 17, 413–421.
[CrossRef] [PubMed]
3. Zhang, X.; Liu, S.; Li, Y.; Wang, Y.; Tian, M.; Liu, G. Long-term effectiveness and cost-effectiveness of
metformin combined with liraglutide or exenatide for type 2 diabetes mellitus based on the CORE diabetes
model study. PLoS ONE 2016, 11, e0156393. [CrossRef] [PubMed]
4. Araújo, F.; Fonte, P.; Santos, H.A.; Sarmento, B. Oral delivery of glucagon-like peptide-1 and analogs:
Alternatives for diabetes control? J. Diabetes Sci. Technol. 2012, 6, 1486–1497. [CrossRef] [PubMed]
5. Tella, S.H.; Rendell, M.S. Glucagon-like polypeptide agonists in type 2 diabetes mellitus: Efficacy and
tolerability, a balance. Ther. Adv. Endocrinol. Metab. 2015, 6, 109–134. [CrossRef] [PubMed]
6. Crane, J.; McGowan, B. The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity. Ther. Adv.
Chronic Dis. 2016, 7, 92–107. [CrossRef] [PubMed]
7. Lin, Y.; Krogh-Andersen, K.; Pelletier, J.; Marcotte, H.; Östenson, C.G.; Hammarström, L. Oral delivery
of pentameric glucagon-like peptide-1 by recombinant lactobacillus in diabetic rats. PLoS ONE 2016, 11,
e0162733. [CrossRef] [PubMed]
8. Shamekhi, F.; Tamjid, E.; Khajeh, K. Development of chitosan coated calcium-alginate nanocapsules for oral
delivery of liraglutide to diabetic patients. Int. J. Biol. Macromol. 2018, 120, 460–467. [CrossRef] [PubMed]
9. Knudsen, L.B.; Lau, J. The discovery and development of liraglutide and semaglutide. Front. Endocrinol.
2019, 10, 155. [CrossRef] [PubMed]
10. Ma, S.; We, L.; Yang, H.; Deng, S.; Jevnikar, A.M. Emerging technologies to achieve oral delivery of GLP-1 and
GLP-1 analogs for treatment of Type 2 diabetes mellitus (T2DM). Can. J. Biotechnol. 2017, 1, 1–10. [CrossRef]
11. Araujo, F.; Shrestha, N.; Gomes, M.J.; Herranz-Blanco, B.; Liu, D.; Hirvonen, J.; Granja, P.L.; Santos, H.A.;
Sarmento, B. In vivo dual-delivery of glucagon like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP4)
inhibitor through composites prepared by microfluidics for diabetes therapy. Nanoscale 2016, 1, 10706–10713.
[CrossRef] [PubMed]
Pharmaceutics 2019, 11, 599 12 of 13
12. Araújo, F.; Shrestha, N.; Shahbazi, M.A.; Fonte, P.; Mäkilä, E.M.; Salonen, J.J.; Hirvonen, J.T.; Granja, P.L.;
Santos, H.A.; Sarmento, B. The impact of nanoparticles on the mucosal translocation and transport of GLP-1
across the intestinal epithelium. Biomaterials 2014, 35, 9199–9207. [CrossRef] [PubMed]
13. Ismail, R.; Csóka, I. Novel strategies in the oral delivery of antidiabetic peptide drugs—Insulin, GLP 1 and
its analogs. Eur. J. Pharm. Biopharm. 2017, 115, 257–267. [CrossRef] [PubMed]
14. Zhang, X.; Sun, M.; Zheng, A.; Cao, D.; Bi, Y.; Sun, J. Preparation and characterization of insulin-loaded
bioadhesive PLGA nanoparticles for oral administration. Eur. J. Pharm. Sci. 2012, 45, 632–638. [CrossRef]
[PubMed]
15. Reix, N.; Parat, A.; Seyfritz, E.; van der Werf, R.; Epure, V.; Ebel, N.; Danicher, L.; Marchioni, E.; Jeandidier, N.;
Pinget, M.; et al. In vitro uptake evaluation in Caco-2 cells and in vivo results in diabetic rats of insulin-loaded
PLGA nanoparticles. Int. J. Pharm. 2012, 437, 213–220. [CrossRef] [PubMed]
16. Wang, M.; Zhang, Y.; Feng, J.; Gu, T.; Dong, Q.; Yang, X.; Sun, Y.; Wu, Y.; Chen, Y.; Kong, W. Preparation,
characterization, and in vitro and in vivo investigation of chitosan-coated poly (d,l-lactide-co-glycolide)
nanoparticles for intestinal delivery of exendin-4. Int. J. Nanomed. 2013, 8, 1141–1154. [CrossRef]
17. Sheng, J.; Han, L.; Qin, J.; Ru, G.; Li, R.; Wu, L.; Cui, D.; Yang, P.; He, Y.; Wang, J. N-trimethyl chitosan
chloride-coated PLGA nanoparticles overcoming multiple barriers to oral insulin absorption. ACS Appl.
Mater. Interfaces 2015, 7, 15430–15441. [CrossRef] [PubMed]
18. Deli, M.A. Potential use of tight junction modulators to reversibly open membranous barriers and improve
drug delivery. Biochim. Biophys. Acta Biomembr. 2009, 1788, 892–910. [CrossRef] [PubMed]
19. Kamei, N.; Morishita, M.; Eda, Y.; Ida, N.; Nishio, R.; Takayama, K. Usefulness of cell-penetrating peptides to
improve intestinal insulin absorption. J. Control Release 2008, 132, 21–25. [CrossRef] [PubMed]
20. Khafagy, E.S.; Morishita, M.; Kamei, N.; Eda, Y.; Ikeno, Y.; Takayama, K. Efficiency of cell-penetrating
peptides on the nasal and intestinal absorption of therapeutic peptides and proteins. Int. J. Pharm. 2009, 381,
49–55. [CrossRef] [PubMed]
21. Kamei, N.; Nielsen, E.J.B.; Khafagy, E.S.; Takeda-Morishita, M. Noninvasive insulin delivery: The great
potential of cell-penetrating peptides. Ther. Deliv. 2013, 4, 315–326. [CrossRef] [PubMed]
22. Nielsen, E.J.B.; Yoshida, S.; Kamei, N.; Iwamae, R.; Khafagy, E.S.; Olsen, J.; Rahbek, U.L.; Pedersen, B.L.;
Takayama, K.; Takeda-Morishita, M. In vivo proof of concept of oral insulin delivery based on a
co-administration strategy with the cell-penetrating peptide penetratin. J. Control Release 2014, 189, 19–24.
[CrossRef] [PubMed]
23. Bocsik, A.; Walter, F.R.; Gyebrovszki, A.; Fülöp, L.; Blasig, I.; Dabrowski, S.; Ötvös, F.; Tóth, A.; Rákhely, G.;
Veszelka, S.; et al. Reversible opening of intercellular junctions of intestinal epithelial and brain endothelial
cells with tight junction modulator peptides. J. Pharm. Sci. 2016, 105, 754–765. [CrossRef] [PubMed]
24. Bocsik, A.; Gróf, I.; Kiss, L.; Ötvös, F.; Zsíros, O.; Daruka, L.; Fülöp, L.; Vastag, M.; Kittel, Á.; Imre, N.; et al.
Dual action of the PN159/KLAL/MAP peptide: Increase of drug penetration across Caco-2 intestinal barrier
model by modulation of tight junctions and plasma membrane permeability. Pharmaceutics 2019, 11, 73.
[CrossRef] [PubMed]
25. Ismail, R.; Sovány, T.; Gácsi, A.; Ambrus, R.; Katona, G.; Imre, N.; Csóka, I. Synthesis and statistical
optimization of poly (lactic-co-glycolic acid) nanoparticles encapsulating GLP1 analog designed for oral
delivery. Pharm. Res. 2019, 36, 99. [CrossRef] [PubMed]
26. Pallagi, E.; Ismail, R.; Paal, T.L.; Csoka, I. Initial risk assessment as part of the quality by design in peptide
drug containing formulation development. Eur. J. Pharm. Sci. 2018, 122, 160–169. [CrossRef] [PubMed]
27. Kürti, L.; Veszelka, S.; Bocsik, A.; Dung, N.T.K.; Ózsvári, B.; Puskás, L.G.; Kittel, Á.; Szabó-Révész, P.;
Deli, M.A. The effect of sucrose esters on a culture model of the nasal barrier. Toxicol. Vitr. 2012, 26, 445–454.
[CrossRef] [PubMed]
28. Kiss, L.; Walter, F.R.; Bocsik, A.; Veszelka, S.; Ózsvári, B.; Puskás, L.G.; Szabó-Révész, P.; Deli, M.A. Kinetic
analysis of the toxicity of pharmaceutical excipients cremophor EL and RH40 on endothelial and epithelial
cells. J. Pharm. Sci. 2013, 102, 1173–1181. [CrossRef] [PubMed]
29. Hellinger, É.; Veszelka, S.; Tóth, A.E.; Walter, F.; Kittel, Á.; Bakk, M.L.; Tihanyi, K.; Háda, V.; Nakagawa, S.;
Duy, T.D.H.; et al. Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2,
and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models. Eur. J. Pharm. Biopharm. 2012,
82, 340–351. [CrossRef] [PubMed]
Pharmaceutics 2019, 11, 599 13 of 13
30. Kiss, L.; Hellinger, É.; Pilbat, A.M.; Kittel, Á.; Török, Z.; Furedi, A.; Szakács, G.; Veszelka, S.; Sipos, P.;
Ózsvári, B.É.; et al. Sucrose esters increase drug penetration, but do not inhibit p-glycoprotein in Caco-2
intestinal epithelial cells. J. Pharm. Sci. 2014, 103, 3107–3119. [CrossRef] [PubMed]
31. Fonte, P.; Araújo, F.; Silva, C.; Pereira, C.; Reis, S.; Santos, H.A.; Sarmento, B. Polymer-based nanoparticles
for oral insulin delivery: Revisited approaches. Biotechnol. Adv. 2014, 33, 1342–1354. [CrossRef] [PubMed]
32. Aung, M.M.; Slade, K.; Freeman, L.A.R.; Kos, K.; Whatmore, J.L.; Shore, A.C.; Gooding, K.M. Locally
delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with
and without type 2 diabetes. Diabetologia 2019, 62, 1701–1711. [CrossRef] [PubMed]
33. Fredenberg, S.; Wahlgren, M.; Reslow, M.; Axelsson, A. The mechanisms of drug release in
poly(lactic-co-glycolic acid)-based drug delivery systems—A review. Int. J. Pharm. 2011, 415, 34–52.
[CrossRef] [PubMed]
34. Dinarvand, R.; Sepehri, N.; Manoochehri, S.; Rouhani, H.; Atyabi, F. Polylactide-co-glycolide nanoparticles
for controlled delivery of anticancer agents. Int. J. Nanomed. 2011, 6, 877–895. [CrossRef] [PubMed]
35. Xu, F.; Wang, K.Y.; Wang, N.; Li, G.; Liu, D. Bioactivity of a modified human glucagon-like peptide-1.
PLoS ONE 2017, 12, e0171601. [CrossRef] [PubMed]
36. Silva, A.L.; Rosalia, R.A.; Sazak, A.; Carstens, M.G.; Ossendorp, F.; Oostendorp, J.; Jiskoot, W. Optimization
of encapsulation of a synthetic long peptide in PLGA nanoparticles: Low-burst release is crucial for efficient
CD8+ T cell activation. Eur. J. Pharm. Biopharm. 2013, 83, 338–345. [CrossRef] [PubMed]
37. Xiong, S.; George, S.; Yu, H.; Damoiseaux, R.; France, B.; Ng, K.W.; Loo, J.S.C. Size influences the cytotoxicity
of poly (lactic-co-glycolic acid) (PLGA) and titanium dioxide (TiO2) nanoparticles. Arch. Toxicol. 2013, 78,
1075–1086. [CrossRef] [PubMed]
38. Platel, A.; Carpentier, R.; Becart, E.; Mordacq, G.; Betbeder, D.; Nesslany, F. Influence of the surface
charge of PLGA nanoparticles on their in vitro genotoxicity, cytotoxicity, ROS production and endocytosis.
J. Appl. Toxicol. 2016, 36, 434–444. [CrossRef] [PubMed]
39. Silva, A.M.; Alvarado, H.L.; Abrego, G.; Martins-Gomes, C.; Garduño-Ramirez, M.L.; García, M.L.;
Calpena, A.C.; Souto, E.B. In vitro cytotoxicity of oleanolic/ursolic acids-loaded in PLGA nanoparticles in
different cell lines. Pharmaceutics 2019, 11, 362. [CrossRef] [PubMed]
40. Cui, K.; Chen, S.; Houston, M.; Quay, S. Tight Junction Modulator Peptide PN159 for Enhanced Mucosal
Delivery of Therapeutic Compounds. US20060062758A1, 23 March 2006.
41. Trier, S.; Linderoth, L.; Bjerregaard, S.; Strauss, H.M.; Rahbek, U.L.; Andresen, T.L. Acylation of salmon
calcitonin modulates in vitro intestinal peptide flux through membrane permeability enhancement. Eur. J.
Pharm. Biopharm. 2015, 96, 329–337. [CrossRef] [PubMed]
42. Gupta, V.; Doshi, N.; Mitragotri, S. Permeation of insulin, calcitonin and exenatide across Caco-2 monolayers:
Measurement using a rapid, 3-day system. PLoS ONE 2013, 8, e57136. [CrossRef] [PubMed]
43. Lanza, R.; Langer, R.; Vacanti, J.P. Principles of Tissue Engineering, 4th ed.; Academic Press: Cambridge, MA,
USA, 2013. [CrossRef]
44. Cohen-Sela, E.; Chorny, M.; Koroukhov, N.; Danenberg, H.D.; Golomb, G. A new double emulsion solvent
diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles. J. Control Release 2009,
133, 90–95. [CrossRef] [PubMed]
45. Yoo, H.S.; Park, T.G. Biodegradable nanoparticles containing protein-fatty acid complexes for oral delivery
of salmon calcitonin. J. Pharm. Sci. 2004, 93, 488–495. [CrossRef]
46. Panyam, J.; Dali, M.M.; Sahoo, S.K.; Ma, W.; Chakravarthi, S.S.; Amidon, G.L.; Levy, R.J.; Labhasetwar, V.
Polymer degradation and in vitro release of a model protein from poly(d,l-lactide-co-glycolide) nano-and
microparticles. J. Control Release 2003, 92, 173–187. [CrossRef]
47. Datrie, M.; Schumann, M.; Wieprecht, T.; Winkler, A.; Beyermann, M.; Krause, E.; Matsuzaki, K.; Murase, O.;
Bienert, M. Peptide helicity and membrane surface charge modulate the balance of electrostatic and
hydrophobic interactions with lipid bilayers and biological membranes.Biochemistry 1996, 24, 35–38. [CrossRef]
48. Arouri, A.; Dathe, M.; Blume, A. The helical propensity of KLA amphipathic peptides enhances their binding
to gel-state lipid membranes. Biophys. Chem. 2013, 180–181, 10–21. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
